Solid Biosciences (SLDB) Revenue (2021 - 2022)
Solid Biosciences (SLDB) reported Revenue of $6.2 million for Q2 2022, up 71.65% on a YoY basis from $3.6 million in Q2 2021, and up 220.47% sequentially from $1.9 million in Q1 2022.
Solid Biosciences (SLDB) Revenue (2021 - 2022) Analysis & Trends
Solid Biosciences (SLDB) has 2 years of Revenue data on file, last reported at $6.2 million in Q2 2022.
- For the quarter ending Q2 2022, Revenue rose 71.65% year-over-year to $6.2 million; the trailing twelve-month figure through Mar 2023 stood at $6.2 million (down 49.48% YoY), and the FY2022 full-year result was $8.1 million, down 40.57% from the prior year.
- Revenue improved to $6.2 million in Q2 2022, from $1.9 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $6.2 million in Q2 2022 to a low of $1.9 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Solid Biosciences | 858.62 Mn | 858.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 6.17 Mn |
| Mar 31, 2022 | 1.93 Mn |
| Dec 31, 2021 | 3.15 Mn |
| Sep 30, 2021 | 3.54 Mn |
| Jun 30, 2021 | 3.59 Mn |
| Mar 31, 2021 | 3.34 Mn |